NCT03327857 - Neihulizumab (ALTB-168) in Patients With Steroid-refractory Acute Graft-versus-host Disease or Treatment-refractory Acute Graft-versus-host Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2018

Primary Completion Date

September 30, 2022

Study Completion Date

December 31, 2022

Conditions

Steroid-refractory Acute Graft-versus-Host DiseaseTreatment-refractory Acute Graft-versus-Host Disease

Interventions

BIOLOGICAL

Neihulizumab (ALTB-168)

"Single dose phase: Patients will receive single dose of Neihulizumab based on the protocol escalation criteria.~Multiple dose phase: Parients will receive weekly doses of Neihulizumab for 4 weeks."

Trial Locations (13)

30322

Emory University, Atlanta

33136

University of Miami - Sylvester Comprehensive Cancer Center, Miami

44106

University Hospitals Seidman Cancer Center, Cleveland

48109

University of Michigan, Ann Arbor

53226

Medical College of Wisconsin, Milwaukee

55455

University of Minnesota, Minneapolis

60637

University of Chicago, Chicago

66205

The University of Kansas Cancer Center, Westwood

77030

Baylor College of Medicine-Houston Methodist & Texas Children's Hospital, Houston

90095

David Geffen School of Medicine at UCLA, Los Angeles

91010

City of Hope, Duarte

98109

Fred Hutchinson Cancer Research Center, Seattle

02215

Dana Farber Cancer Center, Boston